Treat ER+ight: Canadian prospective observational study in post-menopausal HR+HER2- advanced breast cancer women—First interim analysis (IA)
| Autor: | Stephen Chia, Sabrina R. Perri, Josee-Anne Roy, Catherine Doyle, Nadia Califaretti, Susan Dent, Cristiano Ferrario |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
medicine.medical_specialty Pediatrics business.industry medicine.medical_treatment Cancer medicine.disease Interim analysis Targeted therapy Clinical trial 03 medical and health sciences 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Internal medicine medicine Observational study 030212 general & internal medicine Dosing Family history Adverse effect business |
| Zdroj: | Journal of Clinical Oncology. 35:1067-1067 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2017.35.15_suppl.1067 |
| Popis: | 1067Background: Treat ER+ight is the first Canadian real-world study enrolling patients (pts) previously exposed to NSAI therapy and currently receiving endocrine therapy (ET) alone or in combination with targeted therapy (ET+TT). Methods: This first planned IA describes baseline parameters and adverse event (AE) prevention strategies adopted by 16 centers since Feb 2016 upon enrolling pts initiating ET or ET+TT. Results: See Table.Conclusions: This IA suggests that pts initiating ET+TT are younger, have a better ECOG status, mostly visceral disease and receive more prophylactic/proactive AE prevention therapies. Insights into real-world dosing and sequence will be presented. Clinical trial information: NCT02753686.Baseline characteristicsOverall(n=72)ET(n=34)ET+TT(n=38)Age, median yrs (range)69.0 (37.0 – 88.0)71.5 (37.0 – 88.0)65.0 (39.0 – 80.0)Family history of BC, n (%)26 (36.1)11 (32.4)15 (39.5)ECOG 0-1, n (%)46 (63.9)19 (55.9)27 (71.1)Time from diagnosis, median yrs (range)---Primary5.1 (0.1-37.4)5.0... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|